Exicure, Inc. (NASDAQ:XCUR) is painting the town red after peaking in February 2021.
XCUR lost 8.33% and ended Thursday’s trading session at $1.54. Volume traded stood at 0.66 million shares, up almost 50% of its average daily volume of 0.36 million. After opening at $1.66, the stock touched a high and low of $1.73 and $1.47 respectively.
Brian C. Bock Appointed as CFO
- The appointment of Brian C. Bock was announced by Exicure Inc., a gene regulatory pioneer and immunotherapeutic drug utilizing spherical nucleic acid technology.
- Mr. Brian C. Bock was appointed as the company’s Chief Financial officer effective immediately.
- Mr. Bock got his qualification from the Northern Arizona University in B.S. in Finance. He also has over 20 years of experience in life science investment banking, mergers and acquisitions. He has served in Lincoln international, JMP securities and RBC capital markets.
- Mr. Bock is also entitled to an inducement award as per the NASDAQ listing rule. He has the option to purchase 600,000 of the company’s common stock at the exercise price of $1.54 per share.
Brian C. Bock says “Exicure’s proprietary SNA platform technology holds great potential for treating unmet neurological and rare diseases. I am pleased to be joining such a talented and dedicated team,”
XCUR closed near its 52-Weeks Low of $1.38 and breached its second Pivot point 1.480 below. Now the question is where will it stop and what will be the bottom. Additional pivot points to watch are 1.460 below and 1.560 and 1.580 above.